Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report ...

The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without ...

Shares of Charles River Laboratories International Inc. slipped 3.01% to $145.99 Tuesday, on what proved to be an all-around ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

MedFluencers, the physician-founded agency renowned for expert management of compliant and impactful healthcare social media campaigns, has partnered with Tulane University to introduce the ...

Boston Scientific Corporation will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, at 8:00 a.

Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and ...

Xaar plc (LON:XAR – Get Free Report)’s share price rose 10.6% on Tuesday following insider buying activity. The stock traded as high as GBX 115.12 ($1.49) and last traded at GBX 104 ($1.34).